Celltrion eyes M&A in Europe, $3.3 bn Zymfentra sales: chairman

WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...

S.Korean anti-obesity drugmakers eye niche demand

The global weight management market has entered a new chapter following the arrival of blockbuster weight-loss medication Wegovy, and South Korean l...

HK inno.N to release K-CAB in MENA market

South Korean bio-health company HK inno.N announced on Tuesday that it signed a contract with Saudi Arabian local pharmaceutical company Tabuk Pharm...

Blackstone signs over $1 bn deal with MBK for 1st exit in Korea

Private equity giant Blackstone Inc. is set to mark its first exit from South Korea by selling a 71.25% stake in the holding firm of Geo-Young Corp....

Samsung begins new drug development for rare diseases

Samsung Bioepis Co., a biosimilar development unit of South Korea’s top conglomerate Samsung Group, has begun its new drug development busines...

Drug maker Boryung targets its highest-ever sales in 2024

Boryung Corp., formerly Boryung Pharmaceutical Co., aims to join the 1 trillion won ($748 million) sales club this year, driven by new chronic disea...

Celltrion'a autoimmune disease drug Zymfentra makes US debut

South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...

Daewoong Pharmaceutical digitizes DB of 800 mn chemical compounds

South Korea's Daewoong Pharmaceutical announced on Monday that it has established a drug development system Daewoong AI System (DAISY) which combine...

SK Biopharm targets $311 mn for Cenobamate US sales

South Korea's SK Biopharmaceuticals targeted 416 billion won ($311 million) for its epilepsy treatment Cenobamate in the US market this year. SK Bi...

Celltrion, WuXi XDC to develop new antibody-drug conjugates

South Korea’s Celltrion Inc. has signed a business agreement with China’s WuXi XDC to jointly develop new antibody-drug conjugates (ADC)...

Celltrion to export three anticancer drugs to Europe

South Korea’s Celltrion Inc. announced on Thursday that it has secured supply contracts for three anticancer biosimilars in European countries...

LG Chem to start phase 3 for head, neck cancer drug in US

South Korea’s LG Chem Ltd. announced on Wednesday that its US-based subsidiary Aveo Pharmaceuticals will start Phase 3 clinical trials for its...

Orion to buy control of biotech startup LegoChem for $415 mn

South Korea’s snack and confectionery maker Orion Group has agreed to buy a controlling stake in LegoChem Biosciences Inc., a Korean biotech s...

OCI-Hanmi merger to create Korea’s Bayer: OCI Chairman

Merging into one team, OCI Group and Hanmi Pharmaceutical Group will leap forward to be a global novel drug manufacturing and biotechnology innova...

JW Pharma takes gout drug Epaminurad to Malaysia for phase 3

South Korea's JW Pharmaceutical Corp., announced on Monday that it has received approval from the Malaysian National Pharmaceutical Regulatory Age...

Celltrion to expand Yuflyma supply network in Europe

South Korea’s Celltrion Inc. announced on Friday that it will supply its biosimilar Yuflyma (active ingredient: adalimumab) for the treatment ...

Celltrion applies for interchangeability of Yuflyma in US

South Korea's Celltrion Inc. announced on Wednesday that it has applied to the US Food and Drug Administration (FDA) for a modified approval to repl...

Kobiolabs gets US patent for oral obesity drug candidate

Kobiolabs Co., a South Korean microbiome-based new drug development company, announced on Wednesday that it has a patent for Roseburia intestinalis ...

LG Chem out-licenses obesity drug candidate to US firm

LG Chem Ltd. has agreed to license out a rare genetic obesity drug candidate in phase 2 clinical trials to Rhythm Pharmaceuticals Inc., a US biotech...

SK Biopharm, Dong-A ST sign licensing deal of Cenobamate

South Korea's SK Biopharmaceuticals Co. announced on Thursday that it has signed a contract with Dong-A ST to transfer the rights to commercialize t...

MedPacto gets FDA OK for colorectal cancer drug clinical trial

South Korea's biotech company MedPacto Inc. announced on Tuesday that it has got approval from the US Food and Drug Administration (FDA) for its I...

Celltrion to sell portfolio of Takeda drugs to CBC Group

South Korea’s Celltrion Inc. will divest of a portfolio of Takeda Pharmaceutical's prescription medicines sold in Asia to CBC Group, a Singapo...

ViGenCell, NK/T cell lymphoma treatment ‘VT-EBV-N’ designated as orphan drug in Europe

ViGenCell, a company specializing in immune cell therapy, announced on the 19th that its NK/T cell lymphoma treatment "VT-EBV-N" has been designated...

LegoChem Bio, Janssen sign $1.7 bn ADC licensing deal

LegoChem Biosciences Inc. has signed a blockbuster $1.7 billion deal to license out its proprietary antibody drug conjugate (ADC) candidate to Jasse...

J&J seeks US, European approval for drug developed with Yuhan

Global healthcare giant Johnson & Johnson is seeking approval for a lung cancer drug developed with Yuhan Corp., bringing the South Korean pha...

Boryung, HK inno.N to co-market Kanarb, K-CAB

South Korea’s pharmaceutical companies Boryung Corp. and HK inno.N announced on Wednesday that they will start co-marketing for their respec...

Icure wins $2.85 mn lidocaine cataplasm order from Guatemala

South Korea's Icure Pharmaceutical Incorporation announced on Tuesday that it signed a supply contract for the specialized local anesthetic lidoca...

HK inno.N reveals differentiated clinical results for K-CAB

South Korean bio-health company HK inno.N has been expanding its market by steadily announcing differentiated clinical results for its gastroesophag...

Celltrion’s Vegzelma listed on US PBM preferred drug list

South Korea's Celltrion Healthcare Co. announced on Tuesday that its anti-cancer biosimilar Vegzelma (active ingredient: bevacizumab) was listed as ...

ISU Abxis gets patent for Alzheimer drug candidate in Taiwan

South Korea's ISU Abxis Co. announced on Friday that its Alzheimer's treatment candidate ISU203 has received a substance patent registration decisio...